Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Quince Therapeutics, Inc. Frequently Asked Questions
What is the ticker symbol for Quince Therapeutics, Inc.? What does QNCX stand for in stocks?
QNCX is the stock ticker symbol of Quince Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Quince Therapeutics, Inc. (QNCX)?
As of Fri Dec 20 2024, market cap of Quince Therapeutics, Inc. is 78.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of QNCX stock?
You can check QNCX's fair value in chart for subscribers.
Is Quince Therapeutics, Inc. a good stock to buy?
The fair value guage provides a quick view whether QNCX is over valued or under valued. Whether Quince Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Quince Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for QNCX.